• BioAtla

  Led · Debt Financing · Jan 2016

  BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics using proprietary protein discovery, evolution and expression technologies. Its CABs are designed to be active only in specific microphysiological conditions and to reversibly switch on and off between diseased and normal cellular microenvironments. CAB formats include monoclonal antibodies, enzymes, antibody-drug conjugates (ADCs), bispecifics, CAR‑T cells and combination therapies. The company has two programs in Phase 1/2 testing in the United States: BA3011 (a CAB-AXL-ADC) and BA3021 (a CAB-ROR2-ADC). Its investigational CAB CTLA-4 antibody, BA3071, is the subject of a global co-development and collaboration agreement with BeiGene for development, manufacturing and commercialization. BioAtla is led by Jay M. Short, Ph.D., and intends to use recent financing to design, implement and execute clinical programs evolving from its CAB platform. BioAtla is a San Diego- and Beijing-based biotech focused on developing Conditionally Active Biologic (CAB) antibody therapeutics. The company concentrates its research on treatments for cancer. BioAtla is led by Jay M. Short, Ph.D. Recently it completed a $45M financing from the Global BIO Impact Fund. The financing was structured as $15M in equity and $30M in debt. The raise provides capital designated to advance its CAB antibody programs toward clinical and developmental goals. BioAtla is a San Diego-based global biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics. Its patent-protected CAB platform produces immunotherapeutics that are activated in selected microenvironments within the body, such as those indicative of cancerous tumors. CABs can be generated in multiple formats including naked monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and CAR T cells. The company plans to use the investment proceeds to accelerate development of its CAB antibody drug pipeline. The strategic investment is also intended to advance collaborative development of biotherapeutics with biopharmaceutical companies and institutions in China. BioAtla is led by Jay M. Short, Ph.D., who serves as president, chief executive officer and chairman of the board.

No current team members are available.